JP2012527867A5 - - Google Patents

Download PDF

Info

Publication number
JP2012527867A5
JP2012527867A5 JP2011550339A JP2011550339A JP2012527867A5 JP 2012527867 A5 JP2012527867 A5 JP 2012527867A5 JP 2011550339 A JP2011550339 A JP 2011550339A JP 2011550339 A JP2011550339 A JP 2011550339A JP 2012527867 A5 JP2012527867 A5 JP 2012527867A5
Authority
JP
Japan
Prior art keywords
peptide
group
amino acid
apc
ctl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011550339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012527867A (ja
JP5903697B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2010/003488 external-priority patent/WO2010137295A1/en
Publication of JP2012527867A publication Critical patent/JP2012527867A/ja
Publication of JP2012527867A5 publication Critical patent/JP2012527867A5/ja
Application granted granted Critical
Publication of JP5903697B2 publication Critical patent/JP5903697B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011550339A 2009-05-26 2010-05-25 Cdc45lペプチドおよびそれを含むワクチン Active JP5903697B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21713309P 2009-05-26 2009-05-26
US61/217,133 2009-05-26
PCT/JP2010/003488 WO2010137295A1 (en) 2009-05-26 2010-05-25 Cdc45l peptides and vaccines including the same

Publications (3)

Publication Number Publication Date
JP2012527867A JP2012527867A (ja) 2012-11-12
JP2012527867A5 true JP2012527867A5 (enExample) 2013-07-11
JP5903697B2 JP5903697B2 (ja) 2016-04-20

Family

ID=43222423

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011550339A Active JP5903697B2 (ja) 2009-05-26 2010-05-25 Cdc45lペプチドおよびそれを含むワクチン

Country Status (16)

Country Link
US (1) US8586547B2 (enExample)
EP (4) EP3868778A3 (enExample)
JP (1) JP5903697B2 (enExample)
KR (1) KR101765452B1 (enExample)
CN (3) CN102459589B (enExample)
AU (1) AU2010253356B2 (enExample)
BR (1) BRPI1010666B1 (enExample)
CA (3) CA3167451A1 (enExample)
DK (3) DK3208334T3 (enExample)
ES (3) ES2875950T3 (enExample)
IL (1) IL216211A (enExample)
MX (1) MX2011012619A (enExample)
RU (1) RU2562160C2 (enExample)
SG (1) SG176058A1 (enExample)
TW (1) TWI507204B (enExample)
WO (1) WO2010137295A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104066746B (zh) * 2011-10-28 2017-12-05 肿瘤疗法科学股份有限公司 Topk肽及包含它们的疫苗
EP3202783A1 (en) 2016-02-02 2017-08-09 Ecole Polytechnique Fédérale de Lausanne (EPFL) Engineered antigen presenting cells and uses thereof
CN114917189B (zh) 2017-01-25 2024-05-14 奥塞免疫疗法公司 用于肽递送的稳定乳液的制造方法
WO2019056099A1 (en) 2017-09-19 2019-03-28 The University Of British Columbia ANTI-HLA-A2 ANTIBODIES AND METHODS OF USE
WO2019056106A1 (en) 2017-09-20 2019-03-28 The University Of British Columbia NOVEL ANTI-HLA-A2 ANTIBODIES AND USES THEREOF

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
ATE319477T1 (de) 1995-08-03 2006-03-15 Univ Leiden Antigen presentierende bläschen, die von zellen ableiten
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
CA2262006A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US6930170B2 (en) * 1997-06-16 2005-08-16 Genentech, Inc. PRO1184 polypeptides
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
ATE375362T1 (de) 1998-06-25 2007-10-15 Kyogo Itoh Von cyclophilin b abstammende tumorantigen- peptide
AU2002240818C1 (en) 2001-03-14 2008-11-06 Agilent Technologies, Inc. MHC molecule constructs and their uses for diagnosis and therapy
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
DK2261249T3 (en) 2002-09-12 2015-02-16 Oncotherapy Science Inc KDR peptides and vaccines comprising the same
US7915036B2 (en) 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
JP4370409B2 (ja) 2005-06-22 2009-11-25 国立大学法人東北大学 がんの予後予測方法
EP2295570A1 (en) 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
US8053183B2 (en) 2005-07-27 2011-11-08 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
KR101130597B1 (ko) 2005-09-13 2012-04-02 다카라 바이오 가부시키가이샤 T 세포 리셉터 및 그 리셉터를 코드하는 핵산
RU2451521C2 (ru) * 2006-06-16 2012-05-27 Онкотерапи Сайенс, Инк. Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их
US8470534B2 (en) 2006-12-01 2013-06-25 Erik S. Knudsen Methods of predicting resistance or sensitivity to therapies for cancer
TWI441648B (zh) 2007-01-03 2014-06-21 Oncotherapy Science Inc Foxp3胜肽疫苗

Similar Documents

Publication Publication Date Title
JP2012500001A5 (enExample)
JP2012517799A5 (enExample)
JP2011524737A5 (enExample)
JP2010523471A5 (enExample)
HRP20141233T1 (hr) PEPTIDNA CJEPIVA DOBIVENA IZ EphA4
JP2010506826A5 (enExample)
RU2011110504A (ru) Эпитопные пептиды inhbb и вакцины, содержащие данные пептиды
RU2011138160A (ru) Пептиды foxmi и вакцины, содержащие их
RU2009141595A (ru) Пептиды тем8 и содержащие их вакцины
JP2016511221A5 (enExample)
JP2008530975A5 (enExample)
JP2013511958A5 (enExample)
RU2012127358A (ru) Олигопептиды imp-3 и содержащие их вакцины
JP2013523084A5 (enExample)
JP2011522777A5 (enExample)
JP2015529219A5 (enExample)
JP2012520659A5 (enExample)
JP2011529683A5 (enExample)
JP2013517764A5 (enExample)
RU2012136464A (ru) Модифицированные пептиды melk и содержащие их вакцины
JP2012527867A5 (enExample)
JP2014533095A5 (enExample)
RU2014121502A (ru) Пептиды торк и содержащие их вакцины
JP2014519311A5 (enExample)
RU2013158399A (ru) Пептиды sema5b и содержащие их вакцины